Affimed Reports Results for Cancer Therapy in NSCLC Patients
Affimed Reports Results for Cancer Therapy in NSCLC Patients
Affimed N.V. (NASDAQ:AFMD) ("Affimed," or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced updated clinical data from the ongoing AFM24-102 trial of AFM24/atezolizumab combination therapy in heavily pretreated NSCLC patients. Results continue to demonstrate meaningful clinical activity in both NSCLC EGFRwt and EGFRmut patients with good tolerability. In addition, the Company reported findings from a post-hoc exposure-response analysis in patients treated with 480 mg AFM24 showing higher AFM24 exposure is associated with significantly better response rates, improved PFS and overall survival (OS). Based on these data, the future development program for AFM24 will use a dose of 720 mg weekly, a dose that has already been successfully tested in the phase 1 study of AFM24 showing a manageable safety profile.
Affimed N.V.（納斯達克：AFMD）（"Affimed"或"公司"）是一家臨床階段的免疫腫瘤學公司，致力於讓患者恢復其抵抗癌症的固有能力，今天宣佈了來自正在進行的AFM24-102試驗的更新臨床數據，該試驗評估AFM24/阿特珠單抗聯合療法在重度預處理非小細胞肺癌（NSCLC）患者中的效果。結果繼續顯示非小細胞肺癌EGFRwt和EGFRmut患者具有顯著的臨床活性，並且耐受性良好。此外，公司還報告了對480毫克AFM24治療患者進行的事後暴露-反應分析的發現，結果顯示更高的AFM24暴露與顯著更好的反應率、改善的無進展生存期（PFS）和總生存期（OS）相關。根據這些數據，AFM24的未來開發計劃將使用每週720毫克的劑量，這一劑量已經在AFM24的1期研究中成功測試過，並顯示出可控的安全性。